These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34042996)

  • 21. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.
    Yao Y; Guo Y; Lip GYH;
    JAMA Netw Open; 2021 Dec; 4(12):e2140071. PubMed ID: 34932104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis.
    Walkey AJ; Quinn EK; Winter MR; McManus DD; Benjamin EJ
    JAMA Cardiol; 2016 Sep; 1(6):682-90. PubMed ID: 27487456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial.
    Schwamm LH; Kamel H; Granger CB; Piccini JP; Katz JM; Sethi PP; Sidorov EV; Kasner SE; Silverman SB; Merriam TT; Franco N; Ziegler PD; Bernstein RA;
    JAMA Neurol; 2023 Jan; 80(1):99-103. PubMed ID: 36374508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHA
    Parsons C; Patel SI; Cha S; Shen WK; Desai S; Chamberlain AM; Luis SA; Aguilar MI; Demaerschalk BM; Mookadam F; Shamoun F
    Mayo Clin Proc; 2017 Mar; 92(3):360-369. PubMed ID: 28259228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score.
    Chao TF; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Hsieh MH; Chen SA
    Can J Cardiol; 2014 Apr; 30(4):405-12. PubMed ID: 24582725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Huo Y; Piorkowski C; Bollmann A
    Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):281-7. PubMed ID: 24610790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.
    Potpara TS; Stankovic GR; Beleslin BD; Polovina MM; Marinkovic JM; Ostojic MC; Lip GYH
    Chest; 2012 Feb; 141(2):339-347. PubMed ID: 21622553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher.
    Lin YJ; Chao TF; Tsao HM; Chang SL; Lo LW; Chiang CE; Hu YF; Hsu PF; Chuang SY; Li CH; Chung FP; Chen YY; Wu TJ; Hsieh MH; Chen SA
    Europace; 2013 May; 15(5):676-84. PubMed ID: 23193161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Bipolar Disorder or Schizophrenia and Oral Anticoagulation Use in Danish Adults With Incident or Prevalent Atrial Fibrillation.
    Fenger-Grøn M; Vestergaard CH; Ribe AR; Johnsen SP; Frost L; Sandbæk A; Davydow DS
    JAMA Netw Open; 2021 May; 4(5):e2110096. PubMed ID: 33999163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    Kotecha D; Bunting KV; Gill SK; Mehta S; Stanbury M; Jones JC; Haynes S; Calvert MJ; Deeks JJ; Steeds RP; Strauss VY; Rahimi K; Camm AJ; Griffith M; Lip GYH; Townend JN; Kirchhof P;
    JAMA; 2020 Dec; 324(24):2497-2508. PubMed ID: 33351042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Use and Key Predictors for the Use of Wearable Health Care Devices by US Adults: Insights from a National Survey.
    Chandrasekaran R; Katthula V; Moustakas E
    J Med Internet Res; 2020 Oct; 22(10):e22443. PubMed ID: 33064083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the Cox-maze procedure for atrial fibrillation concomitant to mitral and tricuspid valve surgery.
    Ad N; Holmes SD; Massimiano PS; Pritchard G; Stone LE; Henry L
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1426-34; discussion 1434-5. PubMed ID: 24075462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study.
    Melduni RM; Lee HC; Bailey KR; Miller FA; Hodge DO; Seward JB; Gersh BJ; Ammash NM
    Am Heart J; 2015 Nov; 170(5):914-22. PubMed ID: 26542499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices.
    Chen W; Khurshid S; Singer DE; Atlas SJ; Ashburner JM; Ellinor PT; McManus DD; Lubitz SA; Chhatwal J
    JAMA Health Forum; 2022 Aug; 3(8):e222419. PubMed ID: 36003419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting.
    Chan PH; Wong CK; Pun L; Wong YF; Wong MM; Chu DW; Siu CW
    BMJ Open; 2017 Jun; 7(6):e013685. PubMed ID: 28619766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study.
    Fauchier L; Clementy N; Pelade C; Collignon C; Nicolle E; Lip GY
    Stroke; 2015 Sep; 46(9):2432-7. PubMed ID: 26251249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors.
    Abdel-Qadir H; Singh SM; Pang A; Austin PC; Jackevicius CA; Tu K; Dorian P; Ko DT
    JAMA Cardiol; 2021 Aug; 6(8):918-925. PubMed ID: 34009232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant).
    Gažová A; Leddy JJ; Rexová M; Hlivák P; Hatala R; Kyselovič J
    Medicine (Baltimore); 2019 Aug; 98(31):e16560. PubMed ID: 31374021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation.
    Nielsen-Kudsk JE; Korsholm K; Damgaard D; Valentin JB; Diener HC; Camm AJ; Johnsen SP
    JACC Cardiovasc Interv; 2021 Jan; 14(1):69-78. PubMed ID: 33413867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.